Developer docs
API playgroundTry for free, no card

Search company profiles

New Amsterdam Pharma

Full company profile

uuid0000ct7

Namestring
New Amsterdam Pharma
Legal namestring
NewAmsterdam Pharma Corporation
Company typeenum
Public
Founded yearint
2020
Descriptiontext

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company developing oral, non-statin therapies for cardio-metabolic diseases, with primary focus on obicetrapib (TA-8995), a highly selective cholesteryl ester transfer protein (CETP) inhibitor. The compound reduces hepatic cholesterol, upregulates LDL receptor expression, and increases LDL clearance, with Phase 3 trials demonstrating 33–41% LDL-C reduction as monotherapy and 50% with a fixed-dose combination of obicetrapib and ezetimibe. NewAmsterdam is conducting six Phase 3 trials (PREVAIL, BROADWAY, BROOKLYN, TANDEM, REMBRANDT, RUBENS) plus a Phase 2 Alzheimer's program, targeting ASCVD patients, HeFH patients, statin-intolerant patients, and metabolic syndrome/T2D patients. The company is also exploring CETP inhibition in Alzheimer's disease following positive p-tau217 biomarker data showing 20.5% reduction in APOE4/4 carriers.

The company's revenue model relies entirely on future pharmaceutical product sales and licensing royalties, as it is pre-commercial with no material product revenue. In the US, NewAmsterdam is building a direct salesforce led by Chief Commercial Officer BJ Jones (former Biohaven Nurtec ODT launch lead) targeting the >€1B cardiovascular market with 51–100 employees and offices in Naarden (Netherlands HQ), Weston FL, Yardley PA, and Aventura FL. For Europe, NewAmsterdam signed an exclusive licensing deal with Menarini Group (potential deal value exceeding €1 billion in upfronts, milestones, and royalties) covering sales, marketing, and distribution. As of December 31, 2025, the company held approximately $729M in cash following $479M raised in a December 2024 public offering, supporting operations through anticipated EMA approval in H2 2026 and FDA approval post-PREVAIL CVOT readout.

Short descriptiontext

NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib, a proprietary oral CETP inhibitor for lowering LDL-C in cardiovascular disease patients who remain uncontrolled on statin therapy, with EMA approval expected in H2 2026 and US commercialization planned directly while Menarini handles Europe under a €1B+ licensing deal.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAventura, United States
HQ citystring
Aventura
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular disease therapeutics, lipid-lowering therapy, CETP inhibitor drugs, biopharmaceutical development, clinical-stage pharmaceuticals
Industry4 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiovascular Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical stage company planning to commercialize obicetrapib for cardiovascular disease patients with elevated LDL-C. Revenue will come from direct pharmaceutical product sales in markets where approved.

seekingalpha.com
2European Licensing (Menarini)
TypeLicensing Royalties
Description

Licensing deal with Menarini Group for exclusive commercialization rights in Europe, with total potential deal value exceeding €1 billion. This represents a combination of upfront payments, development milestones, and royalty payments on net sales.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib (TA-8995), an oral, highly selective cholesteryl ester transfer protein (CETP) inhibitor for lowering LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH). The lead candidate is being developed as both a monotherapy and a fixed-dose combination with ezetimibe, supported by Phase 3 clinical trials demonstrating 33-50% LDL-C reductions, with an FDA NDA submission and EMA marketing authorization application under review.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 33% LDL-C reduction (BROADWAY trial, p < 0.0001)
+6 more records
Product overview1 text field

New Amsterdam Pharma is a late-stage clinical biopharmaceutical company developing a pipeline of oral, non-statin medicines for cardiovascular disease and other lipid-related conditions. The core product is obicetrapib (TA-8995), a highly selective CETP inhibitor, which is being developed both as a monotherapy and as a fixed-dose combination with ezetimibe. The company has multiple Phase 3 registrational trials underway including PREVAIL (cardiovascular outcomes), BROADWAY, BROOKLYN, TANDEM, REMBRANDT, and RUBENS, as well as Phase 2 programs for Alzheimer's disease and additional indications. The company is also exploring applications of CETP inhibition beyond cardiovascular disease, including potential treatment for Alzheimer's disease and type 2 diabetes.

Product and service2 records
1Obicetrapib (TA-8995)
CategoryCardiovascular Pharmaceuticals
Description

Investigational, oral, highly selective cholesteryl ester transfer protein (CETP) inhibitor being studied as an adjunct to maximally tolerated lipid-lowering therapies for lowering LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH).

2Obicetrapib + Ezetimibe Fixed-Dose Combination
CategoryCardiovascular Pharmaceuticals
Description

Fixed-dose combination of obicetrapib (CETP inhibitor) with ezetimibe (NPC1L1 inhibitor) for patients with ASCVD, HeFH, or CV risk equivalent, designed to provide synergistic LDL-C reduction alongside maximally tolerated lipid-lowering therapies; demonstrated 50% LDL-C reduction in TANDEM Phase 3 trial.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Exclusive licensing agreement for commercialization of obicetrapib in Europe. Total potential deal value exceeds €1 billion. Menarini will handle all commercial activities including sales, marketing, and distribution in European territories. EMA decision expected in H2 2026.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

European commercialization rights exclusively licensed to Menarini Group following regulatory approval.

3Victorian Heart Institute
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Phase 3 clinical partnership for cardiovascular outcomes trial PREVAIL. This partnership was recognized at the Citeline Awards in 2025.

newamsterdampharma.com
Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage company marketing bempedoic acid (Nexletol/Nexlizet), an oral non-statin LDL-C lowering therapy targeting the same statin-intolerant and ASCVD patient population as obicetrapib. Most directly comparable peer given oral mechanism, CV risk-reduction positioning, and overlapping prescriber base.

TypeDirect peer
Description

Markets Vascepa/icosapent ethyl for cardiovascular risk reduction in statin-treated high-triglyceride patients. Directly comparable as a focused cardiovascular outcomes-driven lipid franchise targeting residual CV risk in ASCVD patients on maximally tolerated statins.

TypeBroad incumbent
Description

Markets Leqvio (inclisiran), a twice-yearly subcutaneous siRNA for LDL-C lowering, providing a major competitive alternative to obicetrapib's oral, once-daily profile. Comparable as a broad incumbent in cardiovascular risk management with deep commercial reach globally.

TypeBroad incumbent
Description

Markets Repatha (evolocumab), the leading PCSK9 inhibitor for LDL-C reduction, and was the original developer of obicetrapib before divesting it to NewAmsterdam in 2020. Directly relevant incumbent competitor and historical licensor of the anchor asset.

TypeBroad incumbent
Description

Co-markets Praluent (alirocumab) PCSK9 inhibitor with Sanofi for LDL-C lowering in ASCVD and HeFH. Comparable as an established incumbent in the same physician call point and same non-statin LDL-C lowering category.

TypeDirect peer
Description

Late-stage cardiometabolic company that achieved FDA approval of resmetirom (Rezdiffra) for MASH. Closely comparable as a focused, late-stage biopharma commercializing a first-in-class cardiometabolic therapy with strong KOL backing and a similar go-to-market profile in specialty prescribing channels.

TypeEmerging player
Description

Clinical-stage genetic medicines company developing in vivo base-editing therapies for cardiovascular disease, including LDL-C lowering. Comparable as a next-generation lipid-lowering platform targeting the same ASCVD patient population with a differentiated (one-time treatment) modality.

TypeEmerging player
Description

Develops antisense oligonucleotide therapies including olezarsen for dyslipidemia and cardiometabolic disease. Comparable as an emerging RNA-targeted lipid franchise competing in the residual CV risk space alongside oral and biologic alternatives to obicetrapib.

TypeEmerging player
Description

Cardiometabolic-focused biopharma with acoramidis (Attruby) approved for ATTR cardiomyopathy and a pipeline spanning cardiovascular and metabolic disease. Comparable as a focused late-stage cardiometabolic specialist with KOL credibility and recent cardiovascular launch experience.

TypeDirect peer
Description

Commercial-stage cardiometabolic company marketing Zynquista (sotagliflozin, an SGLT1/2 inhibitor) for heart failure and diabetes. Comparable as a small-cap oral cardiometabolic franchise commercializing through a targeted US specialty sales channel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

New Amsterdam Pharma

Cardiovascular Pharmaceuticalsnewamsterdampharma.com

NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib, a proprietary oral CETP inhibitor for lowering LDL-C in cardiovascular disease patients who remain uncontrolled on statin therapy, with EMA approval expected in H2 2026 and US commercialization planned directly while Menarini handles Europe under a €1B+ licensing deal.

What New Amsterdam Pharma does

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company developing oral, non-statin therapies for cardio-metabolic diseases, with primary focus on obicetrapib (TA-8995), a highly selective cholesteryl ester transfer protein (CETP) inhibitor. The compound reduces hepatic cholesterol, upregulates LDL receptor expression, and increases LDL clearance, with Phase 3 trials demonstrating 33–41% LDL-C reduction as monotherapy and 50% with a fixed-dose combination of obicetrapib and ezetimibe. NewAmsterdam is conducting six Phase 3 trials (PREVAIL, BROADWAY, BROOKLYN, TANDEM, REMBRANDT, RUBENS) plus a Phase 2 Alzheimer's program, targeting ASCVD patients, HeFH patients, statin-intolerant patients, and metabolic syndrome/T2D patients. The company is also exploring CETP inhibition in Alzheimer's disease following positive p-tau217 biomarker data showing 20.5% reduction in APOE4/4 carriers.

The company's revenue model relies entirely on future pharmaceutical product sales and licensing royalties, as it is pre-commercial with no material product revenue. In the US, NewAmsterdam is building a direct salesforce led by Chief Commercial Officer BJ Jones (former Biohaven Nurtec ODT launch lead) targeting the >€1B cardiovascular market with 51–100 employees and offices in Naarden (Netherlands HQ), Weston FL, Yardley PA, and Aventura FL. For Europe, NewAmsterdam signed an exclusive licensing deal with Menarini Group (potential deal value exceeding €1 billion in upfronts, milestones, and royalties) covering sales, marketing, and distribution. As of December 31, 2025, the company held approximately $729M in cash following $479M raised in a December 2024 public offering, supporting operations through anticipated EMA approval in H2 2026 and FDA approval post-PREVAIL CVOT readout.

New Amsterdam Pharma firmographics

Firmographics
Name
New Amsterdam Pharma
Legal name
NewAmsterdam Pharma Corporation
Website
https://newamsterdampharma.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib, a proprietary oral CETP inhibitor for lowering LDL-C in cardiovascular disease patients who remain uncontrolled on statin therapy, with EMA approval expected in H2 2026 and US commercialization planned directly while Menarini handles Europe under a €1B+ licensing deal.
Ownership category
akta.pro rank

New Amsterdam Pharma industry classification

Industry
Product category
Cardiovascular Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Cardiovascular disease therapeutics
  • Lipid-lowering therapy
  • CETP inhibitor drugs
  • Biopharmaceutical development
  • Clinical-stage pharmaceuticals

Where New Amsterdam Pharma is headquartered

Location

Headquarters

HQ city
Aventura
HQ country
United States
HQ region
North America

Offices4 records

Markets served

New Amsterdam Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical stage company planning to commercialize obicetrapib for cardiovascular disease patients with elevated LDL-C. Revenue will come from direct pharmaceutical product sales in markets where approved.
  2. European Licensing (Menarini): Licensing deal with Menarini Group for exclusive commercialization rights in Europe, with total potential deal value exceeding €1 billion. This represents a combination of upfront payments, development milestones, and royalty payments on net sales.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

New Amsterdam Pharma product offering

Product offering

Core offering

NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib (TA-8995), an oral, highly selective cholesteryl ester transfer protein (CETP) inhibitor for lowering LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH). The lead candidate is being developed as both a monotherapy and a fixed-dose combination with ezetimibe, supported by Phase 3 clinical trials demonstrating 33-50% LDL-C reductions, with an FDA NDA submission and EMA marketing authorization application under review.

Product overview

New Amsterdam Pharma is a late-stage clinical biopharmaceutical company developing a pipeline of oral, non-statin medicines for cardiovascular disease and other lipid-related conditions. The core product is obicetrapib (TA-8995), a highly selective CETP inhibitor, which is being developed both as a monotherapy and as a fixed-dose combination with ezetimibe. The company has multiple Phase 3 registrational trials underway including PREVAIL (cardiovascular outcomes), BROADWAY, BROOKLYN, TANDEM, REMBRANDT, and RUBENS, as well as Phase 2 programs for Alzheimer's disease and additional indications. The company is also exploring applications of CETP inhibition beyond cardiovascular disease, including potential treatment for Alzheimer's disease and type 2 diabetes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Obicetrapib (TA-8995) Investigational, oral, highly selective cholesteryl ester transfer protein (CETP) inhibitor being studied as an adjunct to maximally tolerated lipid-lowering therapies for lowering LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH).
  • Obicetrapib + Ezetimibe Fixed-Dose Combination Fixed-dose combination of obicetrapib (CETP inhibitor) with ezetimibe (NPC1L1 inhibitor) for patients with ASCVD, HeFH, or CV risk equivalent, designed to provide synergistic LDL-C reduction alongside maximally tolerated lipid-lowering therapies; demonstrated 50% LDL-C reduction in TANDEM Phase 3 trial.

Quantifiable outcome

  • 33% LDL-C reduction (BROADWAY trial, p < 0.0001)
  • +6 more outcomes

Companies that use New Amsterdam Pharma

Customer profile

Segments5 records

Ideal customer profiles2 records

New Amsterdam Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

New Amsterdam Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Menarini GroupflagshipChannel Partner/ Reseller/ Distributor · 1 January 2022Exclusive licensing agreement for commercialization of obicetrapib in Europe. Total potential deal value exceeds €1 billion. Menarini will handle all commercial activities including sales, marketing, and distribution in European territories. EMA decision expected in H2 2026.
  • Menarini GroupflagshipChannel Partner/ Reseller/ DistributorEuropean commercialization rights exclusively licensed to Menarini Group following regulatory approval.
  • Victorian Heart InstitutecoreStrategic or Co-development PartnerPhase 3 clinical partnership for cardiovascular outcomes trial PREVAIL. This partnership was recognized at the Citeline Awards in 2025.

Scale indicators9 records

Recent moves13 records

Expansion highlights6 records

New Amsterdam Pharma competitors and assessment

Company assessment

Direct peers

  • Esperion Therapeutics: Commercial-stage company marketing bempedoic acid (Nexletol/Nexlizet), an oral non-statin LDL-C lowering therapy targeting the same statin-intolerant and ASCVD patient population as obicetrapib. Most directly comparable peer given oral mechanism, CV risk-reduction positioning, and overlapping prescriber base.
  • Amarin Corporation: Markets Vascepa/icosapent ethyl for cardiovascular risk reduction in statin-treated high-triglyceride patients. Directly comparable as a focused cardiovascular outcomes-driven lipid franchise targeting residual CV risk in ASCVD patients on maximally tolerated statins.
  • Madrigal Pharmaceuticals: Late-stage cardiometabolic company that achieved FDA approval of resmetirom (Rezdiffra) for MASH. Closely comparable as a focused, late-stage biopharma commercializing a first-in-class cardiometabolic therapy with strong KOL backing and a similar go-to-market profile in specialty prescribing channels.
  • Lexicon Pharmaceuticals: Commercial-stage cardiometabolic company marketing Zynquista (sotagliflozin, an SGLT1/2 inhibitor) for heart failure and diabetes. Comparable as a small-cap oral cardiometabolic franchise commercializing through a targeted US specialty sales channel.

Broad incumbents

  • Novartis: Markets Leqvio (inclisiran), a twice-yearly subcutaneous siRNA for LDL-C lowering, providing a major competitive alternative to obicetrapib's oral, once-daily profile. Comparable as a broad incumbent in cardiovascular risk management with deep commercial reach globally.
  • Amgen: Markets Repatha (evolocumab), the leading PCSK9 inhibitor for LDL-C reduction, and was the original developer of obicetrapib before divesting it to NewAmsterdam in 2020. Directly relevant incumbent competitor and historical licensor of the anchor asset.
  • Regeneron: Co-markets Praluent (alirocumab) PCSK9 inhibitor with Sanofi for LDL-C lowering in ASCVD and HeFH. Comparable as an established incumbent in the same physician call point and same non-statin LDL-C lowering category.

Emerging players

  • Verve Therapeutics: Clinical-stage genetic medicines company developing in vivo base-editing therapies for cardiovascular disease, including LDL-C lowering. Comparable as a next-generation lipid-lowering platform targeting the same ASCVD patient population with a differentiated (one-time treatment) modality.
  • Ionis Pharmaceuticals: Develops antisense oligonucleotide therapies including olezarsen for dyslipidemia and cardiometabolic disease. Comparable as an emerging RNA-targeted lipid franchise competing in the residual CV risk space alongside oral and biologic alternatives to obicetrapib.
  • BridgeBio Pharma: Cardiometabolic-focused biopharma with acoramidis (Attruby) approved for ATTR cardiomyopathy and a pipeline spanning cardiovascular and metabolic disease. Comparable as a focused late-stage cardiometabolic specialist with KOL credibility and recent cardiovascular launch experience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

New Amsterdam Pharma social profiles

Digital presence

New Amsterdam Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

New Amsterdam Pharma leadership team

Management profile

Number of profiles

Profiles17 records

New Amsterdam Pharma funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

New Amsterdam Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New Amsterdam Pharma

What does New Amsterdam Pharma do?

NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company developing obicetrapib (TA-8995), an oral, highly selective cholesteryl ester transfer protein (CETP) inhibitor for lowering LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH). The lead candidate is being developed as both a monotherapy and a fixed-dose combination with ezetimibe, supported by Phase 3 clinical trials demonstrating 33-50% LDL-C reductions, with an FDA NDA submission and EMA marketing authorization application under review.

Is New Amsterdam Pharma a public or private company?

New Amsterdam Pharma is a public company. It is classified as public and is currently operating.

When was New Amsterdam Pharma founded?

New Amsterdam Pharma was founded in 2020. It employs 101 to 250 people.

Where is New Amsterdam Pharma based?

New Amsterdam Pharma is headquartered in Aventura, United States, in the North America region.

How does New Amsterdam Pharma make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are european Licensing (Menarini).

Who are New Amsterdam Pharma's main competitors?

Direct peers on record are Esperion Therapeutics, Amarin Corporation, Madrigal Pharmaceuticals and Lexicon Pharmaceuticals. Broad incumbents are Novartis, Amgen and Regeneron. Emerging players are Verve Therapeutics, Ionis Pharmaceuticals and BridgeBio Pharma.

Does New Amsterdam Pharma have an API?

No public API is recorded for New Amsterdam Pharma.

What industry is New Amsterdam Pharma in?

New Amsterdam Pharma's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StRevenue Downgrade: Here's What Analysts Forecast For NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)Analysts downgraded NewAmsterdam Pharma's 2027 revenue forecast to $46m, a 78% improvement over the prior year, while losses rose to $2.09 per share. The consensus price target remained at €46.06, with estimates ranging from €34.08 to €54.70. The company is expected to grow faster than the industry, but the downgrade may prompt market caution.TradingViewCantor Fitzgerald maintains NewAmsterdam Pharma Co at Overweight, raises price target to $61 from $52Cantor Fitzgerald maintained NewAmsterdam Pharma Co at Overweight and raised its price target to $61 from $52, a 17.3% increase. The target implies an upside of 218.0% from the Nov 10 close of $19.18.Investing.comNewAmsterdam Pharma at guggenheim conference: launch and data pathNewAmsterdam Pharma presented its late-stage strategy for obicetrapib at the Guggenheim conference, with Phase III LDL studies complete and a European launch planned by Menarini by end of 2024. The company expects a PREVAIL interim analysis by end of 2024, with DSMB results in Q1 2025, and plans to file the NDA soon after a positive result.American Banking and Market NewsNewAmsterdam Pharma (NASDAQ:NAMS) Stock Gets Price Target Trim from Needham & Company LLCNeedham & Company lowered its price target on NewAmsterdam Pharma from $48 to $46, keeping a buy rating. The company reported Q3 EPS of -$0.14, beating the -$0.47 consensus, with revenue of $19.16 million. Analysts have a consensus target of $48.70.Insider Trading & Hedge Fund DataThe Billionaire-Backed Pharma Play Sitting on a $640M Cash Pile at 52-Week LowsNewAmsterdam Pharma ranked 9th on a list of 10 NASDAQ stocks at 52-week lows, according to a list published by billionaires. The list highlights that many of these companies are building, powering, or renting space for AI, with several reporting record revenue while shares continued to slide.Business & FinancialNewamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NewAmsterdam Pharma granted share options and restricted stock units to six non-executive new hires on November 2, 2026, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $19.56 and vest over four years, while the RSUs vest over three years.Seeking AlphaNewAmsterdam Pharma GAAP EPS of -$0.14 beats by $0.30, revenue of $19.16M beats by $4.11MNewAmsterdam Pharma reported Q3 GAAP EPS of -$0.14, beating by $0.30, and revenue of $19.16M, up 5,374% year-over-year, beating by $4.11M. As of September 30, 2026, cash and marketable securities totaled $643.1 million, down from $728.9 million at year-end 2025.Stock TitanNewAmsterdam Pharma gets EU approval for obicetrapibNewAmsterdam Pharma received European Commission approval for obicetrapib monotherapy and fixed-dose combination with ezetimibe, the first regulatory approval worldwide. The company reported Q3 2026 revenue of $19.2 million and a net loss of $17.4 million, with cash of $643.1 million. It plans the PREVAIL interim analysis in 4Q2026 and topline data from the RUBENS trial around year-end.Business & FinancialNewamsterdam Pharma To Participate At Upcoming Investor Conferences In NovemberNewAmsterdam Pharma will participate in three investor conferences in November 2026, including Guggenheim, Stifel, and Jefferies. Executives Ian Somaiya, Matthew Philippe, and Michael Davidson will join fireside chats, with live webcasts available on the company's investor relations page.Stock TitanNewAmsterdam Pharma to Join 3 November Investor ConferencesNewAmsterdam Pharma management will participate in three healthcare investor conferences on November 10, 11, and 18, 2026, with fireside chats in Boston, New York, and London. The chats will be live-webcasted and archived on the company's investor relations website.